Boehringer

Boehringer Ingelheim Acquires Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches

Retrieved on: 
Tuesday, September 21, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Biotechnology, Neoplasm, Wood, CSO, MHC, Doctor of Philosophy, Cancer, Patient, CEO, Acquisition, Control, Potyvirus, Cell membrane, TCR, Antigen, Â, Ingelheim am Rhein, Research, Dallas–Fort Worth metroplex, Boehringer Ingelheim, Boehringer, Fine chemical, Vaccine

In particular, Abexxas technology could lead to the development of cancer immunotherapies that are effective in a broader range of patients and cancer types.

Key Points: 
  • In particular, Abexxas technology could lead to the development of cancer immunotherapies that are effective in a broader range of patients and cancer types.
  • By expanding our portfolio of antibodies binding novel intracellular tumor antigens, we are striving to develop unique and broadly applicable new immunotherapeutic approaches for cancer patients, added Wood.
  • The prize allowed Abexxa to expand operations into a shared lab space in Cambridge, Massachusetts, to continue its research.
  • Abexxa will continue to operate in the Arlington, Texas, area as a Boehringer Ingelheim family company, collaborating extensively with the colleagues at Boehringer Ingelheims U.S. research site in Ridgefield, Connecticut.

42PLUS1 Successfully Launched Its First Edition of Europe’s Largest Prized Pitch Award With 100 Applications From Over 17 Countries Held at the DxPx Conference US

Retrieved on: 
Wednesday, August 25, 2021
Research, Professional Services, Oncology, Medical Devices, Technology, Science, Biotechnology, Finance, Other Technology, Other Science, Health, Diabetes, Knowledge, Boehringer, Company, SLS, McDermott Will & Emery, Boehringer Ingelheim, Maritime Hotel, GRAIL, Disease, Roman Catholic Diocese of La Crosse, Industry, Precision medicine, MEDICA, Google, Solution, Nigeria Pitch Awards, Conference, Digital health, Initial public offering, Hologic, List of life sciences, Wild card, Technology, Video game, Pharmaceutical industry, DxPx®, SLS Partnering, DXPX®, SLS PARTNERING

The winners of the 42PLUS1 Pitch Award will be elected from a renowned jury of industry experts and investors at the grand finale at the DxPx Conference EU, November 16th in Dusseldorf, Germany.

Key Points: 
  • The winners of the 42PLUS1 Pitch Award will be elected from a renowned jury of industry experts and investors at the grand finale at the DxPx Conference EU, November 16th in Dusseldorf, Germany.
  • The DxPx Conference is an established Industry & Investor Partnering Conference for executives of the Diagnostics, Digital Health, Precision Medicine and Life Science Tools industry.
  • Our mission is to support young companies as well as to promote novel solutions in Diagnostics, Digital Health, Precision Medicine and Life Science Tools, says Lena Ehrenpreis, initiator of the DxPx Conference and the 42PLUS1 Pitch Award.
  • The organizer SLS Partnering is inviting Marc to the DxPx Conference EU, November 16th, to pitch with 7 other finalists for 1,500,000 USD funding.

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

Retrieved on: 
Tuesday, August 3, 2021
Veterinary, Research, Mental health, Infectious diseases, Clinical trials, Cardiology, Biotechnology, Pharmaceutical, Health, Science, Anti-diabetic drugs, Boehringer Ingelheim, Empagliflozin, Boehringer, Economy of Germany, SGLT2 inhibitor, Ingelheim am Rhein, States of Germany, Germany

In July, Boehringer Ingelheim reported a breakthrough in the treatment of heart failure with empagliflozin (marketed as JARDIANCE).

Key Points: 
  • In July, Boehringer Ingelheim reported a breakthrough in the treatment of heart failure with empagliflozin (marketed as JARDIANCE).
  • Boehringer Ingelheim also made progress in the area of neuropsychiatric disorders, including two ongoing phase II trials.
  • Quantum computing holds enormous potential for pharmaceutical research and development, particularly for early research processes in which Boehringer Ingelheim has a high level of expertise.
  • Following a successful financial year 2020, Boehringer Ingelheim continued its positive trend in the first half of 2021.

eTheRNA immunotherapies opens office in Hong Kong to support and build on its growing activities in China and broader Asia-Pacific

Retrieved on: 
Tuesday, August 3, 2021
Finance, Money, BNP Paribas, Financial services, Boehringer Ingelheim, Boehringer, Venture capital, Fortis, CGP

In particular, eTheRNA Asia will focus on supporting business and investor relations in China and especially the relationship between eTheRNA and its strategic partner, China Grand Pharmaceutical and Healthcare Holdings Ltd ('CGP').

Key Points: 
  • In particular, eTheRNA Asia will focus on supporting business and investor relations in China and especially the relationship between eTheRNA and its strategic partner, China Grand Pharmaceutical and Healthcare Holdings Ltd ('CGP').
  • CGP and eTheRNA's relationship is centred on their joint venture company, Nanjing AuroRNA Biotechnology Company Limited.
  • The Company is headquartered in Belgium, with subsidiaries in the USA and Hong Kong, and was established in 2013.
  • eTheRNA is supported by an international group of specialised investors: BNP Fortis Private Equity, Boehringer Ingelheim Venture Funds, Everjoy Fortune PTE.

eTheRNA immunotherapies opens office in Hong Kong to support and build on its growing activities in China and broader Asia-Pacific

Retrieved on: 
Tuesday, August 3, 2021
Finance, Money, BNP Paribas, Financial services, Boehringer Ingelheim, Boehringer, Venture capital, Fortis, CGP

In particular, eTheRNA Asia will focus on supporting business and investor relations in China and especially the relationship between eTheRNA and its strategic partner, China Grand Pharmaceutical and Healthcare Holdings Ltd ('CGP').

Key Points: 
  • In particular, eTheRNA Asia will focus on supporting business and investor relations in China and especially the relationship between eTheRNA and its strategic partner, China Grand Pharmaceutical and Healthcare Holdings Ltd ('CGP').
  • CGP and eTheRNA's relationship is centred on their joint venture company, Nanjing AuroRNA Biotechnology Company Limited.
  • The Company is headquartered in Belgium, with subsidiaries in the USA and Hong Kong, and was established in 2013.
  • eTheRNA is supported by an international group of specialised investors: BNP Fortis Private Equity, Boehringer Ingelheim Venture Funds, Everjoy Fortune PTE.

DGAP-News: Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million) in this Round

Retrieved on: 
Thursday, July 29, 2021
Evotec, Armoured fighting vehicles, Boehringer Ingelheim, Health, Medicine, Topas, OT-62 TOPAS, Boehringer, Arthritis

Topas Therapeutics Extends Series B, Raising Total of 40 Million(~$ 48 Million) in this Round

Key Points: 
  • Topas Therapeutics Extends Series B, Raising Total of 40 Million(~$ 48 Million) in this Round
    The issuer is solely responsible for the content of this announcement.
  • The funding will be used to obtain clinical proof of concept in two programs and to accelerate the Company's proprietary pipeline based on the Topas Particle Conjugates technology platform.
  • Topas will also be advancing several of its pre-clinical-stage programs, including one for the treatment of rheumatoid arthritis and one for Type I diabetes.
  • Topas' investors are: BioMedPartners, Boehringer Ingelheim Venture Fund, EMBL Ventures, Epidarex Capital, Evotec, Gimv and Vesalius Biocapital III.

ImaginAb Announces Extension Of Long-Standing Partnership With Boehringer Ingelheim

Retrieved on: 
Friday, July 23, 2021
Immunology, Branches of biology, Boehringer Ingelheim, Antibody, Boehringer, Health care, Medicine

ImaginAb will receive license fees and payments for providing ongoing technical, clinical, and regulatory support to enable the successful implementation of its CD8 ImmunoPET technology.

Key Points: 
  • ImaginAb will receive license fees and payments for providing ongoing technical, clinical, and regulatory support to enable the successful implementation of its CD8 ImmunoPET technology.
  • Commenting on the announcement, Ian Wilson, Chief Executive Officer of ImaginAb stated:
    "Boehringer Ingelheim were the first to partner with us on our CD8 ImmunoPET agent, and we are delighted we can expand our partnership and enable our technology to be used across multiple clinical programs."
  • Wilson continued: "ImaginAb has a clear aim to become the lead in diagnostic and treatment choices, transforming patient care and helping patients live better and healthier lives.
  • ImaginAb engineer antibody fragments called Minibodies that maintain the exquisite specificity of full-length antibodies while remaining biologically inert in the body.

Boehringer Ingelheim Appoints General Manager of Pawru, Inc.

Retrieved on: 
Wednesday, July 14, 2021
Boehringer Ingelheim, Pharmaceutical companies, Boehringer, Ingelheim am Rhein, Economy of Germany, States of Germany, CircoFLEX

DULUTH, Ga., July 14, 2021 /PRNewswire/ -- Boehringer Ingelheim Animal Health USA Inc. has appointed Bryan Haardt as General Manager of Pawru, Inc., a Boehringer Ingelheim companythat facilitates collaborative pet care by connecting veterinary professionals and pet owners on an innovative digital platform.

Key Points: 
  • DULUTH, Ga., July 14, 2021 /PRNewswire/ -- Boehringer Ingelheim Animal Health USA Inc. has appointed Bryan Haardt as General Manager of Pawru, Inc., a Boehringer Ingelheim companythat facilitates collaborative pet care by connecting veterinary professionals and pet owners on an innovative digital platform.
  • Boehringer Ingelheim announced this year that it had created Pawru as a separate company and would re-brand a service that the company offered nationwide in 2020 as PetPro Connect.
  • Since its founding in 1885, Boehringer Ingelheim has been independent and family owned.
  • In 2020, Boehringer Ingelheim achieved net sales of around $22.33 billion (19.57 billion euros).

Aragen Announces Expansion of Discovery Research Agreement with Boehringer Ingelheim

Retrieved on: 
Tuesday, June 29, 2021
Research, Technology, Other Technology, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Boehringer Ingelheim, Boehringer, Ingelheim am Rhein, States of Germany, Economy of Germany, Germany

Aragen Life Sciences (formerly GVK BIO), a leading Contract Research and Development Organization, headquartered out of Hyderabad, India, announces an expansion of their discovery research agreement with Boehringer Ingelheim, with the goal of accelerating the discovery pipeline of Boehringer Ingelheim.

Key Points: 
  • Aragen Life Sciences (formerly GVK BIO), a leading Contract Research and Development Organization, headquartered out of Hyderabad, India, announces an expansion of their discovery research agreement with Boehringer Ingelheim, with the goal of accelerating the discovery pipeline of Boehringer Ingelheim.
  • This preferred partnership allows Boehringer Ingelheim, a leading research driven pharmaceutical company, to incorporate several design elements, synthesize, profile, and then characterize a wide range of chemotypes against key targets of interest in swift optimization cycles.
  • It has been our privilege to collaborate with the scientists at Boehringer Ingelheim, and we thank them for their trust and confidence in the Aragen team.
  • Aragen Life Sciences Pvt Ltd (Aragen) is a global leader in providing discovery, development and manufacturing solutions for life sciences firms.

xCures raises $12.69 million in Series A funding for their AI-powered precision oncology platform

Retrieved on: 
Wednesday, June 23, 2021
Evidence-based medicine, Precision medicine, Systems biology, Boehringer Ingelheim, Boehringer, Economy of Germany, Germany

This investment, led by Boehringer Ingelheim Venture Fund and joined by Vanedge Capital , Harmonix Fund , Metaplanet , as well as other investors, will be used to accelerate adoption and further development of xCures' AI-Powered platform for precision oncology decision making.

Key Points: 
  • This investment, led by Boehringer Ingelheim Venture Fund and joined by Vanedge Capital , Harmonix Fund , Metaplanet , as well as other investors, will be used to accelerate adoption and further development of xCures' AI-Powered platform for precision oncology decision making.
  • The xCures platform transforms complex unstructured medical data directly from the patient's medical records into structured data suitable for analysis and machine learning.
  • "We're confident that xCures will continue to develop their platform and work to make a meaningful impact for patients."
  • xCures Inc. operates an AI-assisted platform that connects cancer patients and physicians with optimal investigational or approved therapies.